Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): Original data and review of the literature

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 10, 2011, Pages 1398-1406

  Pohl, M ^a   Werner, N ^b   Munding, J ^c   Tannapfel, A ^c   Graeven, U ^d   Nickenig, G ^b   Schmiegel, W ^a,c,e   Reinacher Schick, A ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d KLINIKEN MARIA HILF GMBH   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

anti angiogenic therapy; bevacizumab; biomarker; endothelial progenitor cells; metastatic colorectal cancer; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CD133 ANTIGEN; CD34 ANTIGEN; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COLORECTAL CANCER; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CELL COUNT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; STEM CELLS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80053527559     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1281752     Document Type: Article

References (54)

1. Ferlay A, Charret C, Galitzky J et al. Effects of the perfusion of beta-, beta2-, or beta3-adrenergic agonists or epinephrine on in situ adipose tissue lipolysis measured by microdialysis in underfed ewes. JAnim Sci 2001 79 453-462 (Pubitemid 33614481)
2. Folkman J. Tumour angiogenesis therapeutic implications. N Engl J Med 1971 285 1182-1186
3. Galizia G, Lieto E, Ferraraccio F et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004 10 3490-3499 (Pubitemid 38685457)
4. Takahashi Y, Kitadai Y, Bucana C D. et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995 55 3964-3968
5. Muller Y A., Chen Y, Christinger H W. et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998 6 1153-1167 (Pubitemid 28434118)
6. Yang J C., Haworth L, Sherry R M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 427-434 (Pubitemid 36910021)
7. Ince W L., Jubb A M., Holden S N. et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. JNatl Cancer Inst 2005 97 981-989 (Pubitemid 41430564)
8. Jubb A M., Hurwitz H I., Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. JClin Oncol 2006 24 217-227 (Pubitemid 46622051)
9. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 275 964-967 (Pubitemid 27087709)
10. Tamuta M, Unno K, Yonezawa S et al. In vivo trafficking of endothelial progenitor cells and their possible involvement in tumour neovascularization. Life Sci 2004 75 575-584 (Pubitemid 38670264)
11. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003 9 702-712 (Pubitemid 36749219)
12. Massa M, Rosti V, Ramajoli I et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. JClin Oncol 2005 23 5688-5695
13. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999 18 3964-3972 (Pubitemid 29335849)
14. Hattori K, Heissig B, Wu Y et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Medicine 2002 8 841-849
15. Bertolini F, Shaked Y, Mancuso P et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006 6 835-845 (Pubitemid 44629895)
16. Bertolini F, Mancuso P, Braidotti P et al. The multiple personality disorder phenotypes of circulating endothelial cells in cancer. Biochim Biophys Acta 2009 1796 27-32
17. Pohl M, Werner N, Munding J et al. Biomarker für das Therapieansprechen auf eine antiangiogenetische Therapie beim metastasierten Kolonkarzinom. Z Gastroenterol (Suppl) 2008 46 P111
18. Schmiegel W H., Reinacher-Schick A, Freier W et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumour study group. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S, abs. 4034
19. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 353 999-1007 (Pubitemid 41262334)
20. Rafii S, Meeus S, Dias S et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 2002 13 61-67 (Pubitemid 35418315)
21. Rowand J L., Martin G, Doyle G V. et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007 71 105-113 (Pubitemid 46238939)
22. Beerepoot L V., Mehra N, Vermaat J S. et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004 15 139-145 (Pubitemid 38139616)
23. Willett C G., Boucher Y, Duda D G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. JClin Oncol 2005 23 8136-8139 (Pubitemid 46657433)
24. Ronzoni M, Manzoni M, Mariucci S et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Onc 2010 21 2382-2389
25. Mancuso P, Burlini A, Pruneri G et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001 97 3658-3661
26. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumour. Clin Cancer Res 2007 13 2643-2650 (Pubitemid 46788031)
27. Holden S H., Ryan E, Kearns A et al. Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; ASCO Annual Meeting Proceedings, Abstract No. 3555
28. Jubb A M., Hurwitz H I., Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. JClin Oncol 2006 24 217-227 (Pubitemid 46622051)
29. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006 94 1823-1832 (Pubitemid 43882572)
30. Vermeulen P B., Gasparini G, Fox S B. et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002 38 1564-1579 (Pubitemid 34876495)
31. Kopetz S, Hoff P M., Morris J S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. JClin Oncol 2010 28 453-459
32. Batchelor T T., Sorensen A G., Tomaso E di et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumour vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007 11 83-95 (Pubitemid 46075199)
33. Goede V, Coutelle O, Neuneier J et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. British Journal of Cancer 2010 103 1407-1414
34. Schneider B P., Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. JClin Oncol 2008 26 4672-4678
35. Manegold P, El-Khoueiry A, Lurje G et al. ICAM-1, GRP-78, and NFkB gene polymorphisms and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). JClin Oncol 2008 (May 20 suppl; abstr 4134) 26
36. Singh H, Pohl A, El-Khoueiry A et al. Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). JClin Oncol 2009 27 15s; abstr 4070
37. OBrien C A., Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007 445 106-110 (Pubitemid 46067310)
38. Ricci-Vitiani L, Lombardi D G., Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007 445 111-115 (Pubitemid 46067311)
39. Duda D G., Cohen K S., Di Tomaso E et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. JClin Oncol 2006 24 1449-1453 (Pubitemid 46622012)
40. Lin E H., Hassan M, Li Y et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007 110 534-542 (Pubitemid 47106141)
41. Pohl A, Zhang W, Yang D et al. Association of CD133 polymorphisms and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with either first-line 5-FU+ bevacizumab (BV) or second-line irinotecan (IR)/cetuximab (CB) or IR alone. JClin Oncol 2009 27 15s: abstr 4062
42. Renehan A G., Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008 371 569-578 (Pubitemid 351232031)
43. Dignam J J., Polite B N., Yothers G et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. JNat Cancer Inst 2006 98 1647-1654 (Pubitemid 44811647)
44. Cao Y. Angiogenesis modulates adipogenesis and obesity. JClin Invest 2007 117 2362-2368 (Pubitemid 47494333)
45. Birmingham J M., Busik J V., Hansen-Smith F M. et al. Novel mechanism for obesity induced colon cancer progression. Carcinogenesis 2009 30 690-697
46. Guiu B, Petit J M., Bonnetain F et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010 59 341-347
47. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 2335-2342 (Pubitemid 38702844)
48. Maitland M L., Moshier K, Imperial J et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. JClin Oncol 2006 (Meeting Abstracts) 24 2035
49. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009 20 227-230
50. Murukesh N, Dive C, Jayson G C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010 102 8-18
51. Mross K, Drevs J, Muller M et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005 41 1291-1299 (Pubitemid 40813005)
52. Hahn O M., Yang C, Medved M et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. JClin Oncol 2008 26 4572-4578
53. De Bazelaire C, Alsop D C., George D et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008 14 5548-5554
54. Willett C G., Boucher Y, Di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 10 145-147 (Pubitemid 38524883)